Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment outcome of ductal carcinoma in situ patients treated with postoperative radiation therapy

  • Lim, Yu Jin (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Kim, Kyubo (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Chie, Eui Kyu (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Han, Wonshik (Department of Surgery, Seoul National University College of Medicine) ;
  • Noh, Dong Young (Department of Surgery, Seoul National University College of Medicine) ;
  • Ha, Sung W. (Department of Radiation Oncology, Seoul National University College of Medicine)
  • Received : 2013.11.12
  • Accepted : 2014.01.02
  • Published : 2014.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the outcome of ductal carcinoma in situ (DCIS) patients who underwent surgery followed by radiation therapy (RT). Materials and Methods: We retrospectively reviewed 106 DCIS patients who underwent surgery followed by postoperative RT between 1994 and 2006. Ninety-four patients underwent breast-conserving surgery, and mastectomy was performed in 12 patients due to extensive DCIS. Postoperative RT was delivered to whole breast with 50.4 Gy/28 fx. Tumor bed boost was offered to 7 patients (6.6%). Patients with hormonal receptor-positive tumors were treated with hormonal therapy. Results: The median follow-up duration was 83.4 months (range, 33.4 to 191.5 months) and the median age was 47.8 years. Ten patients (9.4%) had resection margin <1 mm and high-grade and estrogen receptor-negative tumors were observed in 39 (36.8%) and 20 (18.9%) patients, respectively. The 7-year ipsilateral breast tumor recurrence (IBTR)-free survival rate was 95.3%. Resection margin (<1 or ${\geq}1$ mm) was the significant prognostic factor for IBTR in univariate and multivariate analyses (p < 0.001 and p = 0.016, respectively). Conclusion: Postoperative RT for DCIS can achieve favorable treatment outcome. Resection margin was the important prognostic factor for IBTR in the DCIS patients who underwent postoperative RT.

Keywords

References

  1. Bane A. Ductal carcinoma in situ: what the pathologist needs to know and why. Int J Breast Cancer 2013;2013:914053.
  2. Masson S, Bahl A. The management of ductal carcinoma in situ: current controversies and future directions. Clin Oncol (R Coll Radiol) 2013;25:275-82. https://doi.org/10.1016/j.clon.2013.01.007
  3. Siziopikou KP. Ductal carcinoma in situ of the breast: current concepts and future directions. Arch Pathol Lab Med 2013; 137:462-6 https://doi.org/10.5858/arpa.2012-0078-RA
  4. Korean Breast Cancer Society. Breast Cancer Facts & Figures. Seoul: Korean Breast Cancer Society; 2013.
  5. Owen D, Tyldesley S, Alexander C, et al. Outcomes in patients treated with mastectomy for ductal carcinoma in situ. Int J Radiat Oncol Biol Phys 2013;85:e129-34. https://doi.org/10.1016/j.ijrobp.2012.10.020
  6. Hwang ES. The impact of surgery on ductal carcinoma in situ outcomes: the use of mastectomy. J Natl Cancer Inst Monogr 2010;2010:197-9. https://doi.org/10.1093/jncimonographs/lgq032
  7. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011;103:478-88. https://doi.org/10.1093/jnci/djr027
  8. Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2011;12:21-9. https://doi.org/10.1016/S1470-2045(10)70266-7
  9. Holmberg L, Garmo H, Granstrand B, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol 2008;26:1247-52. https://doi.org/10.1200/JCO.2007.12.7969
  10. Donker M, Litiere S, Werutsky G, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 2013;31:4054-9. https://doi.org/10.1200/JCO.2013.49.5077
  11. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 2006;24:1031-6. https://doi.org/10.1200/JCO.2005.02.9975
  12. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:5319-24. https://doi.org/10.1200/JCO.2009.21.8560
  13. Kim KJ, Huh SJ, Park W, et al. Treatment outcome and analysis of the prognostic factors of ductal carcinoma in situ treated with breast conserving surgery and radiotherapy. J Korean Soc Ther Radiol Oncol 2004;22:11-6.
  14. Di Saverio S, Catena F, Santini D, et al. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat 2008;109:405-16. https://doi.org/10.1007/s10549-007-9668-7
  15. Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 2009;27: 1615-20. https://doi.org/10.1200/JCO.2008.17.5182
  16. Wang SY, Chu H, Shamliyan T, et al. Network meta-analysis of margin threshold for women with ductal carcinoma in situ. J Natl Cancer Inst 2012;104:507-16. https://doi.org/10.1093/jnci/djs142
  17. Wong P, Lambert C, Agnihotram RV, David M, Duclos M, Freeman CR. Ductal carcinoma in situ: the influence of the radiotherapy boost on local control. Int J Radiat Oncol Biol Phys 2012;82:e153-8. https://doi.org/10.1016/j.ijrobp.2011.03.045
  18. Rakovitch E, Narod SA, Nofech-Moses S, et al. Impact of boost radiation in the treatment of ductal carcinoma in situ: a population-based analysis. Int J Radiat Oncol Biol Phys 2013;86:491-7. https://doi.org/10.1016/j.ijrobp.2013.02.031
  19. Motwani SB, Goyal S, Moran MS, Chhabra A, Haffty BG. Ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy: a comparison with ECOG study 5194. Cancer 2011;117:1156-62. https://doi.org/10.1002/cncr.25623
  20. McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective randomized trial for "good risk" ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS). In: 2012 American Society of Clinical Oncology Annual Meeting; 2012 Jun 1-5; Chicago, IL, USA. Alexandria, VA: ASCO; 2012.

Cited by

  1. Is radiotherapy necessary for intermediate risk ductal carcinoma in situ after breast conserving surgery? vol.3, pp.1, 2014, https://doi.org/10.1186/2193-1801-3-405
  2. Influence of boost radiotherapy in patients with ductal carcinoma in situ breast cancer: a multicenter, retrospective study in Korea (KROG 11-04) vol.146, pp.2, 2014, https://doi.org/10.1007/s10549-014-3025-4
  3. Proportion and Clinical Outcomes of Postoperative Radiotherapy Omission after Breast-Conserving Surgery in Women with Breast Cancer vol.18, pp.1, 2014, https://doi.org/10.4048/jbc.2015.18.1.50